– April 1, 2013
April 1, 2013
View Issues
-
Oral Sapacitabine for Treating Elderly Patients with AML
In this Phase 2 trial, 105 older patients with acute myeloid leukemia who were either treatment-naïve or at first relapse were treated with one of three schedules of oral sapacitabine: 200 mg twice daily for 7 days (group A), 300 mg twice daily for 7 days (group B), or 400 mg twice daily for 3 days each week for 2 weeks (group C). -
Denosumab for Bone Pain in Metastatic Breast Cancer
Denosumab is more effective than zoledronic acid at preventing pain in women with advanced breast cancer and bone metastases. -
Sunitinib in Older Renal Cell Carcinoma Patients
In a six-site Italian retrospective analysis, treatment of elderly patients with metastatic renal cell carcinoma with sunitinib was shown to be effective but associated with significant toxicity. Although only applied to a subset, pretreatment comprehensive geriatric assessment did not offer predictive value with regard to severe toxicity or efficacy. -
Use of Sorafenib in Advanced HCC Patients with Child-Pugh Class B Liver Dysfunction
Early pivotal trials demonstrating the efficacy of sorafenib for patients with advanced hepatocellular cancer included primarily those with minimal liver dysfunction (Child-Pugh [CP] class A). -
Laparoscopy vs Laparotomy in Early Uterine Cancer: We Still Don’t Know
LAP2 was a randomized, Phase 3 trial to evaluate and compare the modality of surgical staging (laparoscopy vs laparotomy) in endometrial cancer. -
Pharmacology Watch: Is This the End of the Road for Calcium Supplementation?
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions. -
Clinical Briefs in Primary Care Supplement